ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2021

Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy.

Zhiqin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.